Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC By Ogkologos - April 13, 2026 290 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a first-in-human phase I study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Taking Control – Risks vs. Benefits July 14, 2020 Breast Cancer Survivor Earned Yoga Instructor Certification During Chemo. Now She... May 8, 2019 Adding Tucatinib to T-DM1 Improves PFS in Previously Treated HER2-positive Advanced... November 28, 2025 Coping With the Holidays During COVID-19 and Cancer November 24, 2020 Load more HOT NEWS Cancer Survivors Face High Rates of Housing Insecurity Νέα για τον καρκίνο του προστάτη Can we grow the treatments of tomorrow? – That Cancer Conversation First treatment approved in England for advanced bile duct cancer
